Ilya Goldshleger Sells 4,875 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 4,875 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $46.00, for a total transaction of $224,250.00. Following the sale, the insider now directly owns 42,246 shares in the company, valued at approximately $1,943,316. This represents a 10.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, November 18th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $45.00, for a total transaction of $139,500.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total transaction of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00.

RxSight Stock Performance

Shares of NASDAQ RXST traded down $0.39 during mid-day trading on Monday, reaching $44.66. The company’s stock had a trading volume of 482,515 shares, compared to its average volume of 490,375. The stock has a 50-day moving average of $50.14 and a two-hundred day moving average of $53.15. The stock has a market capitalization of $1.80 billion, a P/E ratio of -53.81 and a beta of 1.19. RxSight, Inc. has a 1-year low of $27.07 and a 1-year high of $66.54.

Institutional Investors Weigh In On RxSight

Hedge funds and other institutional investors have recently bought and sold shares of the company. M&G Plc increased its position in RxSight by 12.4% during the second quarter. M&G Plc now owns 159,005 shares of the company’s stock worth $9,540,000 after purchasing an additional 17,577 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of RxSight by 2.7% in the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock valued at $78,634,000 after purchasing an additional 40,500 shares during the period. Algert Global LLC purchased a new position in shares of RxSight in the second quarter valued at approximately $2,488,000. Bank of New York Mellon Corp boosted its stake in shares of RxSight by 17.0% in the second quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company’s stock valued at $7,190,000 after purchasing an additional 17,368 shares during the period. Finally, Caxton Associates LP purchased a new position in shares of RxSight in the first quarter valued at approximately $1,208,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Oppenheimer lowered their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Finally, Wells Fargo & Company reduced their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.